• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Arbutus Biopharma Corporation (Amendment)

    2/14/22 9:36:30 AM ET
    $ABUS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ABUS alert in real time by email
    SC 13G/A 1 p22-0718sc13ga.htm ARBUTUS BIOPHARMA CORPORATION

     

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     
     
    SCHEDULE 13G/A
     
     
    Under the Securities Exchange Act of 1934
     
    (Amendment No.  5)*
     

    Arbutus Biopharma Corporation

    (Name of Issuer)
     

    Common Shares, without par value

    (Title of Class of Securities)
     

    03879J100

    (CUSIP Number)
     

    December 31, 2021

    (Date of event which requires filing of this statement)
     
     
    Check the appropriate box to designate the rule pursuant to which this Schedule 13G is filed:
     
    x Rule 13d-1(b)
    ¨ Rule 13d-1(c)
    ¨ Rule 13d-1(d)
     
    (Page 1 of 7 Pages)

     

    ______________________________

    * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 (the "Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

    CUSIP No. 03879J10013G/APage 2 of 7 Pages

     

    1

    NAMES OF REPORTING PERSONS

    RTW Investments, LP

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5

    SOLE VOTING POWER

    - 0 -

    6

    SHARED VOTING POWER

    2,504,493 Shares

    7

    SOLE DISPOSITIVE POWER

    - 0 -

    8

    SHARED DISPOSITIVE POWER

    2,504,493 Shares

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    2,504,493 Shares

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    1.7%

    12

    TYPE OF REPORTING PERSON

    PN, IA

             

     

    CUSIP No. 03879J10013G/APage 3 of 7 Pages

     

    1

    NAMES OF REPORTING PERSONS

    Roderick Wong

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    United States

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5

    SOLE VOTING POWER

    - 0 -

    6

    SHARED VOTING POWER

    2,504,493 Shares

    7

    SOLE DISPOSITIVE POWER

    - 0 -

    8

    SHARED DISPOSITIVE POWER

    2,504,493 Shares

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    2,504,493 Shares

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    1.7%

    12

    TYPE OF REPORTING PERSON

    IN, HC

             

     

    CUSIP No. 03879J10013G/APage 4 of 7 Pages

     

     

    Item 1(a). NAME OF ISSUER.
       
      The name of the issuer is Arbutus Biopharma Company (the "Company").

     

    Item 1(b). ADDRESS OF ISSUER'S PRINCIPAL EXECUTIVE OFFICES:
       
      The Company's principal executive offices are located at 701 Veterans Circle, Warminster, Pennsylvania 19874.

     

    Item 2(a). NAME OF PERSON FILING:
       
      This statement is filed by:

     

      (i)

    RTW Investments, LP ("RTW Investments"), a Delaware limited partnership, and the investment adviser to certain funds (the "RTW Funds"), with respect to the Shares (as defined in Item 2(d) below) directly held by the RTW Funds; and

     

      (ii) Mr. Roderick Wong ("Mr. Wong"), the Managing Partner and Chief Investment Officer of RTW Investments, with respect to the Shares directly held by the RTW Funds.

     

      The foregoing persons are hereinafter sometimes collectively referred to as the "Reporting Persons."
       
      The filing of this statement should not be construed as an admission that any of the foregoing persons or any Reporting Person is, for the purposes of Section 13 of the Act, the beneficial owner of the Shares reported herein.  

     

    Item 2(b). ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE:
       
      The address of the business office of each of the Reporting Persons is 40 10th Avenue, Floor 7, New York, New York 10014.

     

    Item 2(c). CITIZENSHIP:
       
      RTW Investments is a Delaware limited partnership.  Mr. Wong is a citizen of the United States.

     

    Item 2(d). TITLE OF CLASS OF SECURITIES:
       
      Common Shares, without par value (the "Shares").

     

     

    CUSIP No. 03879J10013G/APage 5 of 7 Pages

     

    Item 2(e). CUSIP NUMBER:
       
      03879J100

     

    Item 3. IF THIS STATEMENT IS FILED PURSUANT TO §§ 240.13d-1(b) OR 240.13d-2(b) OR (c), CHECK WHETHER THE PERSON FILING IS A:

     

      (a) ¨ Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o);
      (b) ¨ Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c);
      (c) ¨ Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c);
      (d) ¨ Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
      (e) x Investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);
      (f) ¨

    Employee benefit plan or endowment fund in accordance with

    Rule 13d-1(b)(1)(ii)(F);

     

      (g) x

    Parent holding company or control person in accordance with

    Rule 13d-1(b)(1)(ii)(G);

      (h) ¨

    Savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

     

      (i) ¨

    Church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act (15 U.S.C. 80a-3);

     

      (j) ¨ Non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J);
      (k) ¨ Group, in accordance with Rule 13d-1(b)(1)(ii)(K).

     

      If filing as a non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J), please
      specify the type of institution:    

     

    Item 4. OWNERSHIP.
       
      The information required by Items 4(a) - (c) is set forth in Rows 5 - 11 of the cover page for each of the Reporting Persons and is incorporated herein by reference.
       
      The percentages set forth herein are calculated based upon approximately 145 million Shares outstanding as of December 31, 2021 as reported in Exhibit 99.1 of the Company's Current Report on Form 8-K, filed with the Securities and Exchange Commission on January 24, 2022.

     

     

    CUSIP No. 03879J10013G/APage 6 of 7 Pages

     

    Item 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS.
       
      If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following: x

     

    Item 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON.
       
      See Item 2.  The RTW Funds have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the Shares reported herein.

     

    Item 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY.
       
      Not applicable.

     

    Item 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP.
       
      Not applicable.

     

    Item 9. NOTICE OF DISSOLUTION OF GROUP.
       
      Not applicable.

     

    Item 10. CERTIFICATION.
       
      Each of the Reporting Persons hereby makes the following certification:
       
      By signing below each Reporting Person certifies that, to the best of his or its knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     

    CUSIP No. 03879J10013G/APage 7 of 7 Pages

     

    SIGNATURES

    After reasonable inquiry and to the best of his or its knowledge and belief, each of the undersigned certify that the information set forth in this statement is true, complete and correct.

    DATED: February 14, 2022

     

     

    RTW INVESTMENTS, LP
         
         
    By: /s/ Roderick Wong  
    Name: Roderick Wong  
    Title: Managing Partner  
       
       
    /s/ Roderick Wong  
    RODERICK WONG  

     

    Get the next $ABUS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ABUS

    DatePrice TargetRatingAnalyst
    3/4/2022$5.50 → $6.00Buy
    Chardan Capital
    2/2/2022$4.00 → $5.00Hold → Buy
    Jefferies
    11/8/2021$7.00 → $9.00Market Outperform
    JMP Securities
    More analyst ratings

    $ABUS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Nguyen Tuan was granted 73,500 shares (SEC Form 4)

    4 - Arbutus Biopharma Corp (0001447028) (Issuer)

    2/2/26 8:21:34 PM ET
    $ABUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President and CEO Androski Lindsay was granted 28,000 shares (SEC Form 4)

    4 - Arbutus Biopharma Corp (0001447028) (Issuer)

    2/2/26 8:21:13 PM ET
    $ABUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Sawhney Roger

    4 - Arbutus Biopharma Corp (0001447028) (Issuer)

    8/6/25 4:08:29 PM ET
    $ABUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABUS
    SEC Filings

    View All

    Arbutus Biopharma Corporation filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - Arbutus Biopharma Corp (0001447028) (Filer)

    2/20/26 4:01:31 PM ET
    $ABUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Arbutus Biopharma Corporation

    SCHEDULE 13G/A - Arbutus Biopharma Corp (0001447028) (Subject)

    2/11/26 1:45:46 PM ET
    $ABUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Arbutus Biopharma Corporation filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - Arbutus Biopharma Corp (0001447028) (Filer)

    2/6/26 4:01:31 PM ET
    $ABUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABUS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Arbutus Reports Third Quarter 2025 Financial Results and Provides Corporate Update

    Strong financial position with cash, cash equivalents and marketable securities of $93.7M  Moderna litigation U.S. trial scheduled for March 2026;Favorable claim construction ruling in Pfizer-BioNTech litigation issued in September 2025  Additional analysis of imdusiran (AB-729) clinical data shows:-46% of Phase 2a patients met criteria to discontinue all treatment-94% of long-term follow-up patients remain off all treatment for up to 2+ years-100% of HBV DNA positive patients in Phase 1b achieved HBV DNA levels belowquantification after only 18 weeks of imdusiran and nucleos(t)ide analogue therapy-All HBV e-antigen positive patients demonstrated dose-dependent HBV e-antigen decreases   WARM

    11/13/25 7:30:00 AM ET
    $ABUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Arbutus Announces Four Abstracts Accepted for Presentation at AASLD - The Liver Meeting® 2025

    Multiple abstracts accepted featuring imdusiran clinical data – highlighting progress toward a potential functional cure for chronic hepatitis B virus AB-101 clinical data abstract recognized as a Poster of Distinction WARMINSTER, Pa., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (NASDAQ:ABUS) ("Arbutus" or the "Company"), a clinical-stage biopharmaceutical company focused on infectious disease, today announced that three abstracts featuring imdusiran data and one abstract featuring AB-101 data, have been accepted for poster presentations at the American Association for the Study of Liver Diseases ("AASLD") – The Liver Meeting 2025, taking place November 7–11 in Washing

    10/7/25 8:00:00 AM ET
    $ABUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Arbutus Reports Second Quarter 2025 Financial Results and Provides Corporate Update

    Q2 total revenue of $10.7M includes previously-deferred revenue following reacquisition of Greater China rights to imdusiran Dr. Roger Sawhney joins the Arbutus Board of Directors following resignation of Anuj Hasija Dr. Harry Janssen joins the Arbutus Scientific Advisory Board Strong financial position with cash, cash equivalents and marketable securities of $98.1M WARMINSTER, Pa., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (NASDAQ:ABUS) ("Arbutus" or the "Company"), a clinical-stage biopharmaceutical company focused on infectious disease, today reported second quarter 2025 financial results and provided a corporate update. "We delivered a strong quarter, marked

    8/6/25 7:30:00 AM ET
    $ABUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABUS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Chardan Capital reiterated coverage on Arbutus Biopharma with a new price target

    Chardan Capital reiterated coverage of Arbutus Biopharma with a rating of Buy and set a new price target of $6.00 from $5.50 previously

    3/4/22 8:38:50 AM ET
    $ABUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Arbutus Biopharma upgraded by Jefferies with a new price target

    Jefferies upgraded Arbutus Biopharma from Hold to Buy and set a new price target of $5.00 from $4.00 previously

    2/2/22 5:11:07 AM ET
    $ABUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    JMP Securities reiterated coverage on Arbutus Biopharma with a new price target

    JMP Securities reiterated coverage of Arbutus Biopharma with a rating of Market Outperform and set a new price target of $9.00 from $7.00 previously

    11/8/21 7:11:01 AM ET
    $ABUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABUS
    Leadership Updates

    Live Leadership Updates

    View All

    Arbutus Reports Fourth Quarter and Year End 2024 Financial Results and Provides Corporate Update

    Claim construction hearing for Pfizer/BioNTech mRNA-LNP vaccine litigation occurred in December 2024; outcome pending Jury trial in Moderna U.S. mRNA-LNP vaccine litigation scheduled for September 2025 Reviewing pipeline and development plans for HBV programs Continued focus on efficient deployment of financial resources and personnel – terminated ATM program and implemented reduction of workforce by 57% in Q1 2025 Board has approved further changes to executive leadership team; including the appointment of Tuan Nguyen as Chief Financial Officer Strong financial position with cash, cash equivalents and investments in marketable securities of $123M WARMINSTER, Pa., March 27, 2025 (GLO

    3/27/25 7:30:00 AM ET
    $ABUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Arbutus Announces Changes to Board of Directors and Appointment of Lindsay Androski as CEO

    WARMINSTER, Pa., Feb. 25, 2025 (GLOBE NEWSWIRE) --  Arbutus Biopharma Corporation (NASDAQ:ABUS) ("Arbutus" or the "Company"), a clinical-stage biopharmaceutical company focused on infectious disease, today announced changes to its board of directors and the appointment of Lindsay Androski, J.D., M.B.A., as Chief Executive Officer. Ms. Androski replaces Michael J. McElhaugh, the Company's Interim President and CEO, effective immediately. Ms. Androski will also serve as a member of the Company's board of directors. Ms. Androski is an MIT-trained biologist with nearly 30 years of experience in the areas of biotechnology, law and academia. She has served in a variety of roles at Roivant. She

    2/25/25 7:00:00 AM ET
    $ABUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Arbutus Announces Retirement of Chief Scientific Officer, Michael J. Sofia, PhD, Effective December 31, 2024

    WARMINSTER, Pa., May 02, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (NASDAQ:ABUS) ("Arbutus" or the "Company"), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a functional cure for people with chronic hepatitis B virus (cHBV) infection, today announced that after a distinguished 38-year career, the Company's co-founder and Chief Scientific Officer, Dr. Michael Sofia, will retire effective December 31, 2024. Dr. Sofia is a globally recognized, Lasker award-winning antiviral drug discovery and development scientist. "On behalf of the entire Company, I want to thank Mike, a renowned industry veteran, for his tremendous contribu

    5/2/24 7:25:00 AM ET
    $ABUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABUS
    Financials

    Live finance-specific insights

    View All

    Arbutus Reports Third Quarter 2024 Financial Results and Provides Corporate Update

    Imdusiran data from IM-PROVE I and IM-PROVE II Phase 2a clinical trials to be presented at upcoming AASLD - The Liver Meeting 2024 Multiple-ascending doses of AB-101 in healthy subjects in the Phase 1a/1b clinical trial were generally safe and well-tolerated with evidence of receptor occupancy Now dosing cHBV patients with AB-101 in Part 3 of the Phase 1a/1b clinical trial Cash runway into the fourth quarter of 2026Conference Call and Webcast Today at 8:45 AM ET WARMINSTER, Pa., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (NASDAQ:ABUS) ("Arbutus" or the "Company"), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a f

    11/6/24 7:30:00 AM ET
    $ABUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Arbutus to Report Third Quarter 2024 Financial Results and Provide Corporate Update

    WARMINSTER, Pa., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (NASDAQ:ABUS), ("Arbutus" or the "Company") a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a functional cure for people with chronic hepatitis B virus (cHBV) infection, today announced that it has scheduled its third quarter 2024 financial results and corporate update for Wednesday, November 6, 2024. The schedule for the press release and conference call/webcast are as follows: • Q3 2024 Press Release:Wednesday, November 6, 2024 at 7:30 a.m. ET• Q3 2024 Conference Call/Webcast:Wednesday, November 6, 2024 at 8:45 a.m. ET   To dial-in for the conference call

    10/23/24 7:30:00 AM ET
    $ABUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Arbutus Reports Second Quarter 2024 Financial Results and Provides Corporate Update

    End-of-treatment data presented at the EASL Congress from two Phase 2a clinical trials supports advancing imdusiran as a potential cornerstone in a HBV functional cure treatment regimen IM-PROVE I clinical trial demonstrated undetectable HBsAg in 33% of patients who were treated with 48 weeks of imdusiran and 24 weeks of IFN and in 67% of these patients with baseline HBsAg less than 1000 IU/mL Prioritizing imdusiran Phase 2b clinical development; eliminating HBV discovery efforts resulting in a reduction in workforce by 40% and extension of expected cash runway into the fourth quarter of 2026 Conference Call and Webcast Today at 8:45 AM ET WARMINSTER, Pa., Aug. 01, 2024 (GLOBE

    8/1/24 7:30:00 AM ET
    $ABUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABUS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Arbutus Biopharma Corporation

    SC 13G/A - Arbutus Biopharma Corp (0001447028) (Subject)

    11/14/24 8:41:06 AM ET
    $ABUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Arbutus Biopharma Corporation

    SC 13G - Arbutus Biopharma Corp (0001447028) (Subject)

    6/10/24 4:50:25 PM ET
    $ABUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D/A filed by Arbutus Biopharma Corporation (Amendment)

    SC 13D/A - Arbutus Biopharma Corp (0001447028) (Subject)

    5/17/24 9:03:23 AM ET
    $ABUS
    Biotechnology: Pharmaceutical Preparations
    Health Care